Інститут підвищення кваліфікації спеціалістів фармації Національного фармацевтичного університету 2 Вищий державний навчальний заклад України «Буковинський державний медичний університет»

The aim of the research is the comparison of professional activity of pharmacists of pharmaceutical institution in Ukraine with different education level in relation to their responsibilities in detection and prevention of adverse reactions (AR) or lack of efficacy of pharmaceutical products (PP), set out in the regulatory documentation on this matter. Materials and methods. The questionnaire was developed and used for pharmacists of pharmaceutical institution, taken training on cycles of postgraduate education during 2016–2018. 70 higher education pharmacists (HEPs) and 80 specialized secondary education pharmacists (SSEP) were inquired. The integrity was evaluated by Fisher's ratio test (F). For convenience of calculation the corresponding functions of MS Excel were used. Results. The majority of SSEPs and HEPs of Ukrainian pharmaceutical institutions are aware of their duty to provide information on AR or lack of efficacy of pharmaceutical products to the Department of Post-authorization Supervision of the State Expert Center of the Ministry of Health of Ukraine and are aware of the regulatory legal documentation on this issue, however they are not active enough to take necessary action filling in the “Adverse drug reaction reporting form” and sending it to the national department. One of the reasons for the underactivity of pharmacy workers, irrespective of their level of education, is the low organization of this process in pharmacy institutions, in particular the absence of the “Adverse drug reaction reporting forms”. Conclusion. Higher education pharmacist are more self-acting in completing “Adverse drug reaction reporting forms” and are less likely to shift their responsibilities to the pharmacy manager. It is critical to resolve the issue on enhancement of efficiency of detecting AR and/or lack of efficacy of PP in pharmacy institutions of Ukraine is to improve the quality of organizational work of pharmacy managers.

No abstract

Aim. To analyze the range and assess the economic availability of nootropic drugs at the Ukrainian pharmaceutical market in 2018. Materials and methods. The study object was information about nootropic drugs available at the pharmaceutical market of Ukraine in 2018 based on the data of the “PharmXplorer” analytical system of the information retrieval company “Morion”. The study included drugs used for the treatment of cerebrovascular diseases from the N06B X pharmacotherapeutic group (according to the ATC classification) – “Other psychostimulative and nootropic drugs”. An indicator of the adequacy of solvency (Ca.s.) was calculated using the data taken on the prices of drugs and the average level of wages for 2018. Results. At the Ukrainian pharmaceutical market in 2018 a wide range of nootropic drugs was presented. The range of retail prices per drug pack was significant, indicating the possibility of a doctor and a patient to choose the drug taking into account its efficacy, safety and affordability. Most trade names of nootropics (52 %) were registered as oral dosage forms, being compliant for patients with chronic cerebral circulatory disorders. 48 % were injectable and infusion drugs, which were topical for acute ischemic attack. Conclusions. It was found that in 2018 drugs containing piracetam, vinpocetine, gamma-aminobutyric acid (GABA) and its derivatives, most drugs based Phenibut (84.6 % of TN) and citicoline (68 % of TN) were highly available to the consumer. Most of the injectable dosage forms of nootropics based on hydrolyzates and tissue derivatives were readily available (50 % of TH) for the average consumer in Ukraine. Considering a fairly wide range of nootropic drugs and the economic availability of most of them the principle of superiority of clinical efficacy, safety and affordability should be the basis for creating and developing new nootropic drugs. Key words: nootropic drugs; assortment; economic affordability; Ukrainian pharmaceutical market.

Aim. Analysis of clinical efficacy of AI for therapy ER (+) HER2 (–) BC, assortment and volume of their consumption in Ukraine in 2017–2020. Materials and methods. Analysis of the assortment and prices and consumption of AI for hormone therapy ER (+) HER2 (–) BC, available on the pharmaceutical market of Ukraine in 2017–2020. Results. A retrospective analysis of the assortment, prices and consumption of AI used for therapy ER (+) HER2 (–) BC, presented on the Ukrainian pharmaceutical market in 2017–2020, was carried out. AI were represented by 3 INNs: anastrozole (L02B G03), letrozole (L02B G04) and exemestane (L02B G06). Market prices in 2017 range from 460.5 to 4163.8; in 2018 – from 486.3 to 1849.0; in 2019 – from 308.7 to 1677.0; and in 2020 – from UAH 449.6 to UAH 2545.3. IA implemented in 2017 – 55,943, in 2018 – 81,284, in 2019 – 126,628, and in 2020 – 160,858.4 thousand packages. Conclusion. There is a clear tendency towards stabilization and even a decrease in prices for AI, if we compare the indicators of 2017 and 2020. There is a clear upward trend in consumption AI are implemented mainly of import production. The price picture for AI has changed somewhat due to the registration of drugs from the letrozole group in 2019-2020, and in 2020 – from the exemestane group.